Neurocrine Biosciences NBIX
NASDAQ NBIX
$174.41 +5.27 (+3.12%)
At close: Nov 11, 2026 · 4:00 PM EST

Neurocrine Biosciences (NBIX) Net Long-Term Debt Issued (Repaid) (2009 - 2022)

Updated

Neurocrine Biosciences (NBIX) recorded Net Long-Term Debt Issued (Repaid) of -$308.8 million in FY2024.

Analysis

Neurocrine Biosciences (NBIX) Net Long-Term Debt Issued (Repaid) (2009 - 2022) Analysis & Trends

Starting with FY2017, Neurocrine Biosciences' Net Long-Term Debt Issued (Repaid) history includes 5 years.

  • The FY2024 figure is the lowest annual Net Long-Term Debt Issued (Repaid) in data going back to FY2017.
  • Per Business Quant data, NBIX's Net Long-Term Debt Issued (Repaid) was -$279 million in FY2022, -$100,000 in FY2021 and -$186.9 million in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net LT Debt (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -1.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 9.98 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 4.91 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -3.05 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -19.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Neurocrine Biosciences 17.13 Bn 13.21 Bn 1.10 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 -279.00 Mn
Mar 31, 2021 -100,000.00
Dec 31, 2020 -186.90 Mn
Sep 30, 2009 496,000.00
API Access

Neurocrine Biosciences Net Long-Term Debt Issued (Repaid) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=NBIX&period=max&api_key=YOUR_API_KEY